Tarafenacin D-tartrate Inhibitor

Tarafenacin D-tartrate is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19nM), ~200 fold selectivity over the M2 receptor.

Salcedo C, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment,of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.
Salcedo C, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment,of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.
Huang X, et al. Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. J Phys Chem B. 2012 Jan 12;116(1):532-41.
Huang X, et al. Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. J Phys Chem B. 2012 Jan 12;116(1):532-41.

Small volumes of Tarafenacin D-tartrate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5755585 is an inhibitor targeting Tarafenacin D-tartrate.